Document Detail

Exploring inhibition of Pdx1, a component of the PLP synthase complex of the human malaria parasite Plasmodium falciparum.
MedLine Citation:
PMID:  23039077     Owner:  NLM     Status:  Publisher    
Malaria tropica is a devastating infectious disease caused by Plasmodium falciparum. This parasite synthesizes vitamin B6 de novo via the pyridoxal 5-phosphate (PLP) synthase enzymatic complex consisting of PfPdx1 and PfPdx2 proteins. Biosynthesis of PLP is largely performed by PfPdx1, ammonia provided by PfPdx2 subunits, is condensed together with d-ribose 5-phosphate (R5P) and dl-glyceraldehyde 3-phosphate (G3P). PfPdx1 accommodates both the R5P and G3P substrates and intricately coordinates the reaction mechanism, which is composed of a series of imine bond formations, leading to the production of PLP. We demonstrate that d-erythrose 4-phosphate (E4P) inhibits PfPdx1 in a dose dependent manner. We propose that the acyclic phospho-sugar E4P, with a C1 aldehyde group similar to acyclic R5P, could interfere with R5P imine bond formations in the PfPdx1 reaction mechanism. Molecular docking and subsequent screening identified the E4P hydrazide analogue, 4-phospho-d-erythronhydrazide (4PEHz), which selectively inhibited PfPdx1 with an IC50 of 43 µM. PfPdx1 contained in the heteromeric PLP synthase complex was shown to be more sensitive to 4PEHz and was inhibited with an IC50 of 16 µM. Moreover, the compound had an IC50 value of 10 µM against cultured P. falciparum intraerythrocytic parasites. To further analyse the selectivity of 4PEHz, transgenic cell lines over-expressing PfPdx1 and PfPdx2 showed that additional copies of the protein complex conferred protection against 4PEHz, implicating that the PLP synthase is directly affected by 4EPHz in vivo. These PfPdx1 inhibitors represent novel lead scaffolds which are capable of targeting PLP biosynthesis, and we propose this as a viable strategy for the development of newer therapeutics against malaria.
Shaun B Reeksting; Ingrid B Müller; Pieter B Burger; Emmanuel S Burgos; Laurent Salmon; Abraham Izak Louw; Lyn-Marie Birkholtz; Carsten Wrenger
Related Documents :
24650937 - Rationale for parp inhibitors in combination therapy with camptothecins or temozolomide...
24205897 - Roles of the n domain of the aaa+ lon protease in substrate recognition, allosteric reg...
23047117 - Amino acids in conserved region ii are crucial to substrate specificity, reaction veloc...
23931437 - Natural products as sources of new lead compounds for the treatment of alzheimer's dise...
9027317 - Structural convergence in the active sites of a family of catalytic antibodies.
16698997 - Ebola virus vp35 protein binds double-stranded rna and inhibits alpha/beta interferon p...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-8
Journal Detail:
Title:  The Biochemical journal     Volume:  -     ISSN:  1470-8728     ISO Abbreviation:  Biochem. J.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2984726R     Medline TA:  Biochem J     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bone tissue response to implant surfaces functionalized with phosphate-containing polymers.
Next Document:  Incidence of beta thalassemia carrier on 1495 couples in preconceptional period.